The University of Pittsburgh (PA) has signed a global licensing deal with Hawthorn Pharmaceuticals, Inc., of Madison, MS, covering a series of monoclonal antibodies for cancer. The antibody portfolio targets a variety of cancers through the cell surface chondrotin sulfate proteoglycan 4 (CSPG4), which plays an important role in signaling pathways regulating tumor cell survival, growth, and motility. Melanoma, triple negative breast cancer, head and neck cancer, leukemia, bone and joint cancer, and brain cancer are some indications present within the scope of the antibodies.
Research indicates the CSPG4 surface antigen is intensely expressed in multiple cancer types and affects downstream signaling. The antigen also is detected on tumor cells with stem cell-like phenotypes, indicating its role in cancer stem cell immunotherapy activity. Under terms of the agreement, Hawthorn will receive an exclusive worldwide license to develop and commercialize the antibody portfolio. “The CSPG4 surface antigen represents a significantly untapped therapy approach which is intensely expressed in a variety of cancers and affects a whole host of downstream signaling activities,” says Rob Lewis, chief scientific officer at Hawthorn.
Source: News Blaze